MedPlus Health Share Price Jumps 11% After Q4 FY26 Net Profit Rises 25% and Revenue Grows 24%

MedPlus Health Services share price gained over 11% in intraday trade after the company reported strong financial results for the March quarter (Q4FY26).

The stock touched an intraday high of ₹1,020.35 on the BSE before trimming some gains. Even after the pullback, the stock remained sharply higher while the broader market traded moderately positive.

MedPlus Health Services Q4 FY26 Profit and Revenue Growth

The company reported healthy growth in both profit and revenue during the quarter.

Key Financial Highlights

• Net Profit: ₹63.97 crore, up 24.6% YoY
• Revenue from Operations: ₹1,864.39 crore, up 23.5% YoY
• EBITDA: ₹107.63 crore, compared to ₹80.33 crore last year
• EBITDA Margin: Improved to 5.8% from 5.3% 

The strong performance was supported by higher sales and improved operational efficiency.

About MedPlus Health

Founded in 2006 by Gangadi Madhukar Reddy, MedPlus is one of India’s largest pharmacy retail chains.

The company operates:

• More than 5,000 stores
• Across 800+ cities
• In 10 Indian states 

It employs over 28,000 full-time employees.

Diversified Business Model

Apart from retail pharmacy, MedPlus also operates in:

• Wholesale distribution
• Manufacturing and contract manufacturing
• Private label pharmaceutical and wellness products
• Diagnostic centres 

The company follows an omni-channel approach, allowing customers to order medicines through physical stores and digital platforms, including WhatsApp.

Read More: Kalpataru Projects Share Price in Focus; Targets ₹30,000 Crore Order Inflow in FY27!

Conclusion

MedPlus Health’s strong Q4 earnings and margin improvement boosted investor confidence, leading to a sharp rise in the stock price. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.